Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.1.1.17 (
ornithine decarboxylase
)
6,351
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
17beta-estradiol (E2) induces
ornithine decarboxylase
(
ODC
) activity in several E2-responsive tissues/cells, and this study investigated the mechanism of hormone-induced transactivation in MCF-7 human breast cancer cells. E2-induced reporter gene (luciferase) activity in MCF-7 cells transfected with a construct (pODC1) containing the -164 to +29 region of the human
ODC
gene promoter linked to bacterial luciferase. This promoter sequence contains GC-rich Sp1 binding sites, CAAT,
LSF
, cAMP response element (CRE), and TATA motifs. Deletion and mutational analysis of the
ODC
promoter showed that both CAAT and
LSF
sites were required for hormone-induced transactivation. Gel mobility shift and DNA footprinting assays indicated that NFYA and
LSF
bound the CAAT and
LSF
motifs, respectively, and GAL4-NFYA/GAL4-
LSF
chimeras were also activated by E2, 8-bromo-cAMP, and protein kinase A (PKA) expression plasmid. However, E2-induced transactivation of GAL4-NFYA and GAL4-
LSF
was blocked by the PKA inhibitor SQ22356 indicating that the mechanism of
ODC
induction by E2 involves upregulation of cAMP/PKA through nongenomic pathways of estrogen action.
...
PMID:Estrogen-dependent regulation of ornithine decarboxylase in breast cancer cells through activation of nongenomic cAMP-dependent pathways. 1522 48